Cognitive functioning and health-related quality of life in long-term anaplastic oligondendroglioma and oligoastrocytoma survivors from the EORTC 26951 study: second follow-up

Cognitive functioning and health-related quality of life in long-term anaplastic oligondendroglioma and oligoastrocytoma survivors from the EORTC 26951 study: second follow-up - Follow-up of anaplastic oligondendroglioma and oligoastrocytoma patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55406

Enrollment

Registered

2019-02-08

Start date

2019-04-25

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oligondendroglioma/oligoastrocytoma primary brain tumor

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients are eligible for participation if they meet the following criteria: 1) They are diagnosed with an anaplastic oligodendroglioma or oligoastrocytoma; 2) They are adults; over 18 years old; 3) They participated in EORTC 26951 study and the first follow-up study; 4) They have signed the informed consent form, or, when unable to decide, their legal representative signed the informed consent form for their participation and the use of their data., Proxies are eligible for participation if they meet the following criteria: 1) The patient is not deemed able to participate (as judged by the treating physician) due to a poor physical or mental condition; 2) The patient has given consent that the proxy may participate on his behalf; 3) In the situation that the patient is deemed unable to decide, the legal representative of the patient has signed the informed consent form to participate; 4) The proxy has signed the informed consent form stating he/she agrees to participate; 5) They are adults; over 18 years old.

Exclusion criteria

Exclusion criteria: Patients are not considered eligible for study participation if: 1) They are not eligible for participating in the study according to the treating physician, due to severe physical or mental impairments hampering filling in the questionnaires or undergoing the cognitive tests; 2) They are unable to communicate adequately., Proxies are not considered eligible for study participation if: 1) They are unable to communicate adequately; 2) The patient, or his/her legal representative, has not signed the informed consent form for proxy participation; 3) They proxy him- or herself has not signed his/her own informed consent form.

Design outcomes

Primary

Measure	Time frame
NCF, HRQoL, mood, fatigue, cognitive complaints and health care utilization.	—

Secondary

Measure	Time frame
Cerebral abnormalities: white matter intensities (WMI) and global cerebral atrophy (GCA) of the latest and earlyer MRI scans.	—

Countries

Netherlands

Outcome results